Aaron Smith, executive director of the National Cannabis Industry Association, was a bit more upbeat. “We appreciate the positive step—however small—of opening up a few additional avenues for medical marijuana research,” he said. “But patients deserve more, and Congress should help them by removing marijuana from the Controlled Substance Act, allowing state programs and medical research to move forward without interference.”

Read more: http://reason.com/blog/2016/08/11/dea-rejects-marijuana-rescheduling-but-e